Coronary Artery Disease Clinical Trial
Official title:
Thrombogenicity Assessment in Patients Treated With Bioresorbable Vascular Scaffolds
NCT number | NCT03033862 |
Other study ID # | 16-2565 |
Secondary ID | |
Status | Withdrawn |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2017 |
Est. completion date | July 1, 2017 |
Verified date | August 2018 |
Source | Inova Health Care Services |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Platelet activation and aggregation, intrinsic thrombogenicity, and biomarkers (fibrinogen, C-reactive protein, platelet endothelial cell adhesion molecule, von Willebrand factor, p-selectin) will be measured and compared following the implantation of Bioreabsorbable Vascular Scaffolds and Drug Eluting Stents.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 1, 2017 |
Est. primary completion date | July 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Subject may be of either sex and of any race, and must be >18 years of age. 2. Subjects undergoing elective PCI due to de novo native coronary artery lesions (length =24 mm) with a reference vessel diameter of =2.5 mm and =3.75 mm. 3. Subject agrees to not participate in any other investigational or invasive clinical study for a period of 3 months following the index procedure. 4. Subject must be willing and able to give appropriate informed consent. 5. The subject is able to read and has signed and dated the informed consent document including authorization permitting release of personal health information approved by the investigator's Institutional Review Board (IRB). Exclusion Criteria: - Hemodynamically unstable at the time of enrollment. - Concurrent or anticipated treatment with warfarin (or derivatives, e.g., phenprocoumon), oral factor Xa inhibitor, or oral direct thrombin inhibitor after enrollment. - GPI use prior to or at the time of PCI. - History of a bleeding, or evidence of active abnormal bleeding. - History at any time of intracranial hemorrhage, intracranial or spinal cord surgery, or a central nervous system tumor or aneurysm. - Documented sustained severe hypertension (systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg) at enrollment. - Severe valvular heart disease, as defined by the American College of Cardiology /American Heart Association. - History within 30 days before enrollment of invasive surgeries (other than mentioned above), or is anticipating one during the course of their study participation, or is planning to have one within 1 month post dosing with the study drug. - History within 30 days before enrollment of TIA and ischemic (presumed thrombotic) stroke/CVA. - Known platelet count <100,000/mm3 within 30 days before enrollment. - Known active hepatobiliary disease, or known unexplained persistent increase in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) activity to two times or more the upper limit of the reference range (upper limit of "normal" [?2xULN]). - Any serious medical comorbidity (e.g., active malignancy) such that the subject's life expectancy is <24 months. - Known current substance abuse at the time of enrollment. - Current participation in any other study of investigational therapy or participation in such a study within the last 30 days. - Known hypersensitivity to any component of the current investigational product. - Female subject of child-bearing potential. - Subject is a woman who is breast-feeding. - Subject is part of the staff personnel directly involved with this study or is a family member of the investigational staff. - LVEF <30% - Subject with known renal insufficiency with an estimated GFR <30 ml/min/1.73m or dialysis at the time of screening - Subject requiring at least two lesion treatment and more suitable for staged PCI. - Moderate or heavy calcification, tortuosity or other conditions are present proximal or within the target segment, reducing the likelihood that the Absorb BVS or XIENCE can be either delivered to or expanded at the lesion. - Extreme angulation (=90°) proximal to or within the target lesion. - Excessive tortuosity (= two 45° angles) proximal to or within the target lesion. - Lesion located within or distal to a diseased arterial graft or SVG. - Aorto-ostial lesion (within 3 mm of the aorta junction). - Lesion located in the left main artery. - Lesion located within 2 mm of the origin of the LAD or LCX. - Lesion involving a bifurcation with a: - side branch = 2 mm in diameter, or - side branch with either an ostial or non-ostial lesion with diameter stenosis > 50%, or - side branch requiring dilatation. - Target vessel contains thrombus. |
Country | Name | City | State |
---|---|---|---|
United States | Inova Fairfax Hospital | Falls Church | Virginia |
Lead Sponsor | Collaborator |
---|---|
Inova Health Care Services |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Thrombogenicity from baseline after device implantation | Platelet activation and aggregation, intrinsic thrombogenicity, and biomarkers will be measured at baseline and then reassessed at multiple time points after the implantation of the study device. | 60 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions
|
N/A |